JIN Yang Pharmaceutical

At a glance

JIN Yang Pharmaceutical filed 27 disclosures in the last 12 months, including 2 insider, 2 5% holder and 1 buyback. The most recent key filing was on Jun 5.

Revenue for 2025 was ₩121B, up 6.5% on 2024. Operating margin was 2.1% against 10.3% a year earlier. Debt was 68% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩65B and operating profit of ₩7.6B.

The 2025 annual report lists 219 employees with an average tenure of 6.6 years and average pay of ₩58.4M, #1049 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩245M each on average. It paid ₩150 per common share in cash dividends, against ₩150 a year earlier (+0%). 최재준 and related parties held 35.30% at year end.

From the 2025 annual report

Staff: 219 (128 men, 91 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩12.6B. Directors and auditors: 5, paid ₩1.2B in total.

Dividends (common shares)

Largest shareholder

최재준 holds 20.80%; with 7 related parties the group holds 35.30% of common shares at year end (from 28.59% at the start of the year).

Individuals paid ₩500M or more

Auditor: 삼정회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary